
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical is a leading player in the infusion therapy market and is well-positioned for growth following its recent acquisitions. Its recent financial performance has been strong, with revenue, EBITDA, and EPS beating consensus estimates. The company's diverse product portfolio, strong financial profile, and potential for share capture make it an attractive investment opportunity. With a solid outlook for revenue growth and margin improvement, I have a positive outlook on the stock with a 12-month price target of $187, based on a P/E multiple of 20x our 2027E adjusted EPS estimate. However, there are some risks to this positive outlook, including potential pricing pressures and geopolitical instability.
Bears say
ICU Medical is facing potential upside drivers such as a pump upgrade cycle and new product launches, but also financial risks from gross margin pressure, uncertain pricing from contract renegotiations, and regulatory challenges. They also have strong potential for revenue and earnings growth and currently hold a number of buy ratings and price targets from other analysts on the market. However, there are concerns about potential challenges from their competitors and their reliance on the US market for a significant portion of their sales.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares